niacinamide has been researched along with Synovioma in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a study evaluating the combination of sorafenib, bevacizumab, and low-dose cyclophosphamide in children with solid tumors, an unexpectedly high incidence of pneumothorax was observed." | 3.81 | Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. ( Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J, 2015) |
| "We have analyzed the expression of SIRT1 and SIRT2 in a series of pediatric sarcoma tumor cell lines and normal cells, and we have evaluated the activity of the sirtuin inhibitor and p53 activator tenovin-6 (Tv6) in synovial sarcoma and rhabdomyosarcoma cell lines." | 3.80 | SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth. ( Brodin, B; D'Arcy, P; de Milito, A; Kis, L; Lain, S; Ma, L; Maruwge, W; Pellegrini, P; Strambi, A, 2014) |
| "Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin." | 2.50 | Emerging therapeutic targets for synovial sarcoma. ( Ferrari, S; Paioli, A; Palmerini, E, 2014) |
| " A partial radiological response was achieved; dosage was reduced to 1." | 1.40 | Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases. ( Basso, U; Maruzzo, M; Montesco, MC; Rastrelli, M; Roma, A; Zanardi, E, 2014) |
| "Synovial sarcoma is a soft tissue sarcoma with poor prognosis and lack of response to conventional cytotoxic chemotherapy." | 1.35 | Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. ( Guo, W; Ji, T; Li, DS; Li, X; Peng, CL; Qu, HY; Ren, T; Tang, S; Tang, XD; Yan, TQ; Yang, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palmerini, E | 1 |
| Paioli, A | 1 |
| Ferrari, S | 1 |
| Zanardi, E | 1 |
| Maruzzo, M | 1 |
| Montesco, MC | 1 |
| Roma, A | 1 |
| Rastrelli, M | 1 |
| Basso, U | 2 |
| Ma, L | 1 |
| Maruwge, W | 1 |
| Strambi, A | 1 |
| D'Arcy, P | 1 |
| Pellegrini, P | 1 |
| Kis, L | 1 |
| de Milito, A | 1 |
| Lain, S | 1 |
| Brodin, B | 1 |
| Interiano, RB | 1 |
| McCarville, MB | 1 |
| Wu, J | 1 |
| Davidoff, AM | 1 |
| Sandoval, J | 1 |
| Navid, F | 1 |
| Brunello, A | 1 |
| Bertuzzi, A | 1 |
| Santoro, A | 1 |
| Peng, CL | 1 |
| Guo, W | 1 |
| Ji, T | 1 |
| Ren, T | 1 |
| Yang, Y | 1 |
| Li, DS | 1 |
| Qu, HY | 1 |
| Li, X | 1 |
| Tang, S | 1 |
| Yan, TQ | 1 |
| Tang, XD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy[NCT01308034] | Phase 1 | 25 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Synovioma
| Article | Year |
|---|---|
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; | 2014 |
5 other studies available for niacinamide and Synovioma
| Article | Year |
|---|---|
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
Topics: Adult; Antineoplastic Agents; Axilla; Combined Modality Therapy; Dioxoles; Epirubicin; Fatal Outcome | 2014 |
SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.
Topics: Acetylation; Animals; Autophagy; Benzamides; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferat | 2014 |
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Fe | 2015 |
Sorafenib is active on lung metastases from synovial sarcoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Ph | 2009 |
Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tu | 2009 |